Author | Branquinha, M. H. | |
Author | Oliveira, S. S. C. | |
Author | Sangenito, L. S. | |
Author | Sodré, C. l. | |
Author | Kneipp, L. F. | |
Author | d`Avila-Levy, Claudia M. | |
Author | Santos, A. L. S. | |
Access date | 2018-01-09T15:17:47Z | |
Available date | 2018-01-09T15:17:47Z | |
Document date | 2015 | |
Citation | BRANQUINHA, Marta H. et al. Cruzipain: An Update on its Potential as Chemotherapy Target against the Human Pathogen Trypanosoma cruzi. Current Medicinal Chemistry, v..22, 11p, 2015. | pt_BR |
ISSN | 0929-8673 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/23887 | |
Language | eng | pt_BR |
Publisher | Bentham Science Publishers | pt_BR |
Rights | restricted access | pt_BR |
Subject in Portuguese | Doença de Chagas | pt_BR |
Subject in Portuguese | Trypanosoma cruzi | pt_BR |
Subject in Portuguese | Quimioterapia | pt_BR |
Subject in Portuguese | doença tropical negligenciada | pt_BR |
Subject in Portuguese | patógeno humano | pt_BR |
Subject in Portuguese | peptidases de cisteína | pt_BR |
Subject in Portuguese | inibidores proteolíticos | pt_BR |
Title | Cruzipain: An Update on its Potential as Chemotherapy Target against the Human Pathogen Trypanosoma cruzi | pt_BR |
Type | Article | pt_BR |
Abstract | Chagas’ disease is one of the most impactful and prevalent neglected tropical diseases in the
Americas, specially affecting the poor and underdeveloped areas in Latin America. Aggravating this
scenario, the medicines used in the current chemotherapy are old, toxic and present a low efficacy to
treat the chronic stage of this disease. In addition, resistant strains of Trypanosoma cruzi, the etiological
agent, are frequently reported. So, there is an imperative requirement for novel chemotherapeutic options to treat this
debilitating disease. In this context, peptidases have emerged as potential targets and, consequently, proteolytic inhibitors
have confirmed to be valuable drugs against several human pathologies. In this line of thinking, T. cruzi produces a major
multifunctional cysteine peptidase, named cruzipain, which directly and/or indirectly orchestrates several physiological
and pathological processes, which culminate in a successful parasitic infection. Taken together, these findings point out
that cruzipain is one of the most important targets for driving a chemotherapy approach against the human pathogen T.
cruzi. The present review summarizes some of the recent advances and failures in this area, with particular emphasis on
recently published studies. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Departamento de Microbiologia Geral. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Departamento de Microbiologia Geral. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Departamento de Microbiologia Geral. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal Fluminense. Instituto de Biologia. Departamento de Biologia Celular e Molecular. Niterói, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ. Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ. Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Departamento de Microbiologia Geral. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Instituto de Química. Programa de Pós-Graduação em Bioquímica. Rio de Janeiro, RJ, Brasil. | pt_BR |
Subject | Chagas Disease | pt_BR |
Subject | Trypanosoma cruzi | pt_BR |
Subject | human pathogen | pt_BR |
Subject | neglected tropical disease | pt_BR |
Subject | cysteine peptidases | pt_BR |
Subject | cruzipain | pt_BR |
Subject | proteolytic inhibitors | pt_BR |
Subject | chemotherapy | pt_BR |
e-ISSN | 1875-533X | |
Embargo date | 2030-01-01 | |